Your browser doesn't support javascript.
loading
The Association of Cardiometabolic, Diet and Lifestyle Parameters With Plasma Glucagon-like Peptide-1: An IMI DIRECT Study.
Eriksen, Rebeca; White, Margaret C; Dawed, Adem Y; Perez, Isabel Garcia; Posma, Joram M; Haid, Mark; Sharma, Sapna; Prehn, Cornelia; Thomas, E Louise; Koivula, Robert W; Bizzotto, Roberto; Mari, Andrea; Giordano, Giuseppe N; Pavo, Imre; Schwenk, Jochen M; De Masi, Federico; Tsirigos, Konstantinos D; Brunak, Søren; Viñuela, Ana; Mahajan, Anubha; McDonald, Timothy J; Kokkola, Tarja; Rutters, Femke; Beulens, Joline; Muilwijk, Mirthe; Blom, Marieke; Elders, Petra; Hansen, Tue H; Fernandez-Tajes, Juan; Jones, Angus; Jennison, Chris; Walker, Mark; McCarthy, Mark I; Pedersen, Oluf; Ruetten, Hartmut; Forgie, Ian; Holst, Jens J; Thomsen, Henrik S; Ridderstråle, Martin; Bell, Jimmy D; Adamski, Jerzy; Franks, Paul W; Hansen, Torben; Holmes, Elaine; Frost, Gary; Pearson, Ewan R.
Affiliation
  • Eriksen R; Section for Nutrition Research, Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK.
  • White MC; Population Health & Genomics, School of Medicine, University of Dundee, Dundee DD1 9SY, UK.
  • Dawed AY; Population Health & Genomics, School of Medicine, University of Dundee, Dundee DD1 9SY, UK.
  • Perez IG; Section for Nutrition Research, Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK.
  • Posma JM; Section of Bioinformatics, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London SW7 2AZ, UK.
  • Haid M; Health Data Research UK, London NW1 2BE, UK.
  • Sharma S; Research Unit Molecular Endocrinology and Metabolism, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health (GmbH), D-85764 Neuherberg, Germany.
  • Prehn C; German Center for Diabetes Research, 85764 Neuherberg, Germany.
  • Thomas EL; Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, 85764 Bavaria, Germany.
  • Koivula RW; Research Unit Molecular Endocrinology and Metabolism, Helmholtz Zentrum Muenchen, German Research Center for Environmental Health (GmbH), D-85764 Neuherberg, Germany.
  • Bizzotto R; Research Centre for Optimal Health, School of Life Sciences, University of Westminster, London W1W 6UW, UK.
  • Mari A; Genetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Skåne University Hospital, 221 00 Malmö, Sweden.
  • Giordano GN; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK.
  • Pavo I; Institute of Neuroscience-National Research Council, 35127 Padua, Italy.
  • Schwenk JM; Institute of Neuroscience-National Research Council, 35127 Padua, Italy.
  • De Masi F; Genetic and Molecular Epidemiology Unit, Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Skåne University Hospital, 221 00 Malmö, Sweden.
  • Tsirigos KD; Eli Lilly Regional Operations GmbH, 1030 Vienna, Austria.
  • Brunak S; Science for Life Laboratory, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH-Royal Institute of Technology, SE-100 44 Stockholm, Sweden.
  • Viñuela A; Department of Health Technology, Kgs Lyngby and The Novo Nordisk Foundation Center for Protein Research, Technical University of Denmark, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Mahajan A; Department of Health Technology, Kgs Lyngby and The Novo Nordisk Foundation Center for Protein Research, Technical University of Denmark, University of Copenhagen, 2200 Copenhagen, Denmark.
  • McDonald TJ; Department of Health Technology, Kgs Lyngby and The Novo Nordisk Foundation Center for Protein Research, Technical University of Denmark, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Kokkola T; Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, DK-2200 Copenhagen, Denmark.
  • Rutters F; Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK.
  • Beulens J; Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
  • Muilwijk M; NIHR Exeter Clinical Research Facility, Royal Devon & Exeter Hospital, Exeter EX2 5DW, UK.
  • Blom M; Department of Medicine, University of Eastern Finland and Kuopio University Hospital, FI-70211 Kuopio, Finland.
  • Elders P; Department of Epidemiology and data Science, Amsterdam Public Health Institute, Amsterdam UMC, location VUMC, 1007 Amsterdam, the Netherlands.
  • Hansen TH; Department of Epidemiology and data Science, Amsterdam Public Health Institute, Amsterdam UMC, location VUMC, 1007 Amsterdam, the Netherlands.
  • Fernandez-Tajes J; Department of Epidemiology and data Science, Amsterdam Public Health Institute, Amsterdam UMC, location VUMC, 1007 Amsterdam, the Netherlands.
  • Jones A; Department of Epidemiology and data Science, Amsterdam Public Health Institute, Amsterdam UMC, location VUMC, 1007 Amsterdam, the Netherlands.
  • Jennison C; Department of Epidemiology and data Science, Amsterdam Public Health Institute, Amsterdam UMC, location VUMC, 1007 Amsterdam, the Netherlands.
  • Walker M; The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, 2200 Copenhagen, Denmark.
  • McCarthy MI; Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
  • Pedersen O; NIHR Exeter Clinical Research Facility, Royal Devon & Exeter Hospital, Exeter EX2 5DW, UK.
  • Ruetten H; Department of Mathematical Sciences, University of Bath, Bath BA2 7AY, UK.
  • Forgie I; Institute of Cellular Medicine (Diabetes), Newcastle University, Newcastle upon Tyne NE3 1DQ, UK.
  • Holst JJ; Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 7LE, UK.
  • Thomsen HS; Wellcome Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
  • Ridderstråle M; NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford OX3 7LH, UK.
  • Bell JD; The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Adamski J; Sanofi-Aventis Deutschland GmbH, R&D, 65926 Frankfurt am Main, Germany.
  • Franks PW; Population Health & Genomics, School of Medicine, University of Dundee, Dundee DD1 9SY, UK.
  • Hansen T; The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Holmes E; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Frost G; Faculty of Medical and Health Sciences, University of Copenhagen, 2200 Copenhagen, Denmark.
  • Pearson ER; Novo Nordisk Fonden Tuborg Havnevej 19, 2900 Hellerup, Denmark.
J Clin Endocrinol Metab ; 109(9): e1697-e1707, 2024 Aug 13.
Article de En | MEDLINE | ID: mdl-38686701
ABSTRACT
CONTEXT The role of glucagon-like peptide-1 (GLP-1) in type 2 diabetes (T2D) and obesity is not fully understood.

OBJECTIVE:

We investigate the association of cardiometabolic, diet, and lifestyle parameters on fasting and postprandial GLP-1 in people at risk of, or living with, T2D.

METHODS:

We analyzed cross-sectional data from the two Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) cohorts, cohort 1 (n = 2127) individuals at risk of diabetes; cohort 2 (n = 789) individuals with new-onset T2D.

RESULTS:

Our multiple regression analysis reveals that fasting total GLP-1 is associated with an insulin-resistant phenotype and observe a strong independent relationship with male sex, increased adiposity, and liver fat, particularly in the prediabetes population. In contrast, we showed that incremental GLP-1 decreases with worsening glycemia, higher adiposity, liver fat, male sex, and reduced insulin sensitivity in the prediabetes cohort. Higher fasting total GLP-1 was associated with a low intake of wholegrain, fruit, and vegetables in people with prediabetes, and with a high intake of red meat and alcohol in people with diabetes.

CONCLUSION:

These studies provide novel insights into the association between fasting and incremental GLP-1, metabolic traits of diabetes and obesity, and dietary intake, and raise intriguing questions regarding the relevance of fasting GLP-1 in the pathophysiology T2D.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: État prédiabétique / Diabète de type 2 / Régime alimentaire / Glucagon-like peptide 1 / Mode de vie Limites: Adult / Aged / Female / Humans / Male / Middle aged Langue: En Journal: J Clin Endocrinol Metab Année: 2024 Type de document: Article Pays d'affiliation: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: État prédiabétique / Diabète de type 2 / Régime alimentaire / Glucagon-like peptide 1 / Mode de vie Limites: Adult / Aged / Female / Humans / Male / Middle aged Langue: En Journal: J Clin Endocrinol Metab Année: 2024 Type de document: Article Pays d'affiliation: Royaume-Uni